Stay updated on Risankizumab in PsA Patients: Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.

Latest updates to the Risankizumab in PsA Patients: Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedNo additions or deletions were detected between the two screenshots; the Study Details page content and layout appear unchanged.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check41 days agoChange DetectedSummary of changes: added a government operating-status notice and a new 196-week clinical trial publication citation, and updated the software version from v3.1.0 to v3.2.0; the prior version tag v3.1.0 was removed.SummaryDifference2%

- Check48 days agoChange DetectedThe page updates to Revision: v3.1.0 and removes several drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the content.SummaryDifference0.1%

- Check55 days agoChange DetectedStandardizes location naming from ‘Tatarstan Republic’ to ‘Tatarstan, Respublika’ and from ‘Tatarstan Republic, Russia’ to ‘Tatarstan, Respublika, Russia’ for the Kazan address.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision updated to v3.0.2 and the Back to Top element was removed; core content, pricing, stock, and time-slot information remain unchanged.SummaryDifference0.1%

- Check70 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

Stay in the know with updates to Risankizumab in PsA Patients: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.